Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

SHA:603707 Revenue

Nanjing King-Friend Biochemical Pharmaceutical had revenue of 1.08B CNY in the quarter ending September 30, 2026, with 14.13% growth. This brings the company's total for the last twelve months to 4.07B, up 8.23% year-over-year. In the year 2025, Nanjing King-Friend Biochemical Pharmaceutical had annual revenue of 3.99B with 1.71% growth. That makes Nanjing King-Friend Biochemical Pharmaceutical the 10,146th largest company in the world by revenue and 1,651st in China.

• Revenue (ttm): 4.07B
• Revenue Growth: +8.23%
• P/S Ratio: 3.52
• Revenue / Employee: 2.61M
• Employees: 1,558
• Market Cap: 14.33B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Preparations 3.52B 88.1%
• Standard heparin API 400.73M 10.0%
• CDMO and Other Products 68.61M 1.7%
• Other 5.55M 0.1%

By Geography

Chart

• Foreign 3.21B 80.3%
• China 785.65M 19.7%

Fiscal year ended Dec 31, 2025 See the full SHA:603707 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.99B	67.09M	1.71%
Dec 31, 2024	3.92B	-7.80M	-0.20%
Dec 31, 2023	3.93B	218.67M	5.89%
Dec 31, 2022	3.71B	26.03M	0.71%
Dec 31, 2021	3.69B	771.81M	26.48%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 6, 2026

Data Sources Report a data error